Search

Ansuvimab

[A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018 … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.

Inositol nicotinate

Inositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.

Omacetaxine mepesuccinate

Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies … Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML.

Sacituzumab govitecan

approval for the treatment of mTNBC patients who have undergone two or more prior therapies. … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

Vismodegib

Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

Gramicidin D

Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution. … Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix.

Mobocertinib

[L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (

Cladribine

[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes.

PRO 2000

PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.